| 1.38 -0.08 (-5.48%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.93 | 1-year : | 3.8 |
| Resists | First : | 2.51 | Second : | 3.25 |
| Pivot price | 2.15 |
|||
| Supports | First : | 1.29 | Second : | 1.08 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 2.21 |
| MA(100) : | 3.53 |
MA(250) : | 7.68 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 5.6  |
D(3) : | 4.7 |
| RSI | RSI(14): 28.4 |
|||
| 52-week | High : | 18.79 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VNRX ] has closed above bottom band by 20.0%. Bollinger Bands are 100.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
VolitionRx Limited is an international epigenetics firm that specializes in pioneering advanced blood tests. These diagnostics are developed to aid in the global detection of various cancers and other diseases. Their innovative product suite includes Nu.Q, engineered for cancer detection; Nu.Q Nets, which monitors immune system health; Nu.Q Vet, a cancer screening solution tailored for animal applications; Nu.Q Capture, designed to enhance diagnostic precision by concentrating samples; and Nu.Q Discover, a specialized platform for nucleosome profiling. The cornerstone of their blood test technology is their proprietary Nucleosomics platform. The company maintains its headquarters in Austin, Texas.
Wed, 10 Jun 2026
VolitionRx Enters Securities Purchase Agreement With Investors to Raise Capital - TradingView
Tue, 09 Jun 2026
VolitionRx (NYSE: VNRX) prices $4.6M stock offering with $2.3M warrant upside - Stock Titan
Tue, 09 Jun 2026
VolitionRx (NYSE: VNRX) to Offer 2.96M Shares and 1.48M Warrants - Stock Titan
Mon, 08 Jun 2026
VolitionRx stock tumbles on $4.6M offering priced at discount By Investing.com - Investing.com South Africa
Sun, 07 Jun 2026
VolitionRx Announces Pricing of $4.6 Million Public Offering - New Castle News
Sun, 07 Jun 2026
Epigenetics firm VolitionRx prices $4.6M deal with $2.3M in potential warrant proceeds - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|